Innate Pharma S.A.
IPH.PA · PAR
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | €12,622 | €51,901 | €49,639 | €12,112 |
| % Growth | -75.7% | 4.6% | 309.8% | – |
| Cost of Goods Sold | €51,980 | €56,022 | €51,663 | €47,004 |
| Gross Profit | -€31,859 | €5,619 | €6,011 | -€34,892 |
| % Margin | -252.4% | 10.8% | 12.1% | -288.1% |
| R&D Expenses | €51,980 | €56,022 | €51,663 | €47,004 |
| G&A Expenses | €20,025 | €11,748 | €14,473 | €15,991 |
| SG&A Expenses | €17,722 | €11,748 | €22,436 | €25,524 |
| Sales & Mktg Exp. | €0 | €0 | €7,963 | €9,533 |
| Other Operating Expenses | -€49,986 | -€49,482 | -€10,663 | -€47,004 |
| Operating Expenses | €19,716 | €18,288 | €63,436 | €25,524 |
| Operating Income | -€51,575 | -€12,669 | -€24,629 | -€47,825 |
| % Margin | -408.6% | -24.4% | -49.6% | -394.9% |
| Other Income/Exp. Net | €2,104 | €5,099 | -€547 | €2,347 |
| Pre-Tax Income | -€56,959 | -€7,570 | -€57,972 | -€45,478 |
| Tax Expense | -€7,488 | €0 | €0 | €0 |
| Net Income | -€49,471 | -€7,570 | -€58,103 | -€52,809 |
| % Margin | -391.9% | -14.6% | -117.1% | -436% |
| EPS | -0.61 | -0.094 | -0.73 | -0.74 |
| % Growth | -548.2% | 87.1% | 1.4% | – |
| EPS Diluted | -0.61 | -0.094 | -0.73 | -0.66 |
| Weighted Avg Shares Out | 60,926 | 60,926 | 60,926 | 60,926 |
| Weighted Avg Shares Out Dil | 81,052 | 80,453 | 79,640 | 79,543 |
| Supplemental Information | – | – | – | – |
| Interest Income | €6,079 | €3,177 | €546 | €327 |
| Interest Expense | €3,975 | €640 | €288 | €312 |
| Depreciation & Amortization | €1,994 | €5,091 | €4,424 | €4,596 |
| EBITDA | -€50,990 | -€1,839 | -€61,295 | -€43,229 |
| % Margin | -404% | -3.5% | -123.5% | -356.9% |